期刊
ONCOTARGET
卷 8, 期 28, 页码 45274-45285出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.16786
关键词
GRO-alpha; CXCR2; bladder cancer; epithelial-mesenchymal transition; recurrence
资金
- Shanghai Municipal Commission of Health and Family Planning [201440511]
- National Natural Science Foundation of China for Youths [81602238, 81001136]
- National Natural Science Foundation of China [81170637]
- Shanghai Committee of Science and Technology General Program for Medicine [11JC1402302]
- Military Fund for Health Care [CWS13BJ09]
- Youth Talent Sailing Program of Shanghai Science and Technology Committee [17YF1425400]
- Youth Foundation of Second Military Medical University [2016QN17]
- Key Project of Science and Innovation Foundation of Shanghai Ministry of Education [14zz084]
Non-muscle invasive bladder cancers (NMIBC) are typically treated by transurethral resection with intravesical chemotherapy. However, the post-therapeutic incidence of tumor recurrence and progression to muscle invasive disease is high, and the underlying mechanism(s) remains unknown. In this study, we observed that recurrent bladder cancer cells exhibit a mesenchymal phenotype, which is initiated by the autocrine GRO-alpha signaling. Mechanically, the chemotherapeutic drug epidoxorubicin induces GRO-alpha expression in primary bladder cancer cells at G1/S phase via p38-dependent activation of NF-kappa B. GRO-alpha phosphorylation of Snail on Ser246 supports Snail's accumulation in the nucleus, and thereby promotes transcription repression activity of Snail from E-cadherin promoters. In accordance, disrupting the GRO-alpha-Snail axis in NMIBC represents a promising alternative to prevent post-therapeutic tumor progression and recurrence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据